|
|
|
|
Research and Markets: Competitor Analysis: B7 - CD28/CTLA-4 Pathway for Treatment of Autoimmune Diseases or Cancer
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/a3a94e/competitor_analysi) has announced the addition of the "" report to their offering.The present Competitive Intelligence Report about the B7 - CD28/CTLA-4...
|
|
|
Research and Markets: Competitor Analysis: B7 - CD28/CTLA-4 Pathway for Treatment of Autoimmune Diseases or Cancer
DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/a3a94e/competitor_analysi) has announced the addition of the "" report to their offering.The present Competitive Intelligence Report about the B7 - CD28/CTLA-4...
|
|
|
Viron Reports Positive Proof of Concept Results in Arthritis for its VT-346 anti-TNF Therapeutic
LONDON, ON, March 16 /PRNewswire/ -- Viron Therapeutics Inc.announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved...
|
|
|
Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis
Viron Therapeutics Inc.announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose...
|
|
|
Autoimmune Hepatitis Type 2 Arising in PFAPA Syndrome: Coincidences or Possible Correlations
Corte CD et al.The authors suppose that the dysregulation in innate immunity that is typical of patients with PFAPA could trigger autoimmune disorders such as autoimmune hepatitis in susceptible subjects. Autoimmune Hepatitis Type 2 Arising in PFAPA...
|
|
|
Autoimmune kidney diseases
Segelmark M et al.Autoimmune kidney diseases.
|
|
|
Queen Mary, University of London: Pinpointing immune system disturbances in celiac disease
Today's Medical & Research News Queen Mary, University of London Pinpointing immune system disturbances in celiac disease March 15th, 2010 Printer-Friendly Version Autoimmune Disease Autoimmune Disorder Coeliac Disease Dentistry Diagnostics...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
Autoimmune Diseases Breaking News News source: Business Wire Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR),...
|
|
|
BiomedReports: News and FDA Updates for Hi-Tech Pharmacal (NASDAQ...
Companies: Hi-Tech Pharmacal Co., Inc.(HITK), Idera Pharmaceuticals Inc (IDRA) BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
Idera Pharmaceuticals, Inc.Rating: Related Stocks: Text Size: Idera Pharmaceuticals, Inc. (IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that...
|
|
|
News and FDA Updates for Hi-Tech Pharmacal (NASDAQ:HITK), Idera (Nasdaq:IDRA)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
News and FDA Updates for Hi-Tech Pharmacal (NASDAQ:HITK), Idera (Nasdaq:IDRA)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
News and FDA Updates for Hi-Tech Pharmacal (NASDAQ:HITK), Idera (Nasdaq:IDRA)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
CAMBRIDGE, Mass.(BUSINESS WIRE) Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil....
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief Executive Officer and...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on
- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief Executive Officer and...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D.
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D.
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
(BUSINESS WIRE) ----Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
(BUSINESS WIRE) ----Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
CAMBRIDGE, Mass.Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th
BusinessWire - Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D. Phil., Chief Executive...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, S
hock, Inflammation and Sepsis CAMBRIDGE, Mass.- (BUSINESS WIRE) - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR),...
|
|
|
Idera Pharmaceuticals to Present an Overview of Toll-like Receptor Antagonist Program at 8th World Congress on Trauma, Shock, Inflammation and Sepsis
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced that Sudhir Agrawal, D.
|
